RATIONALE: Caspofungin acetate may be effective in treating fungal infections in patients
with acute myeloid leukemia or myelodysplastic syndrome who are receiving treatment for their
cancer. It is not yet known whether caspofungin acetate is more effective when treatment
starts after development of a fever or after the infection is shown in laboratory test, chest
x-ray, or CT scan.
PURPOSE: This randomized phase III trial is studying the best time to start caspofungin
acetate therapy in treating patients with acute myeloid leukemia or myelodysplastic syndrome
that is newly diagnosed or in first relapse.
Phase:
Phase 3
Details
Lead Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC